AVTX-803
Phase 3Small molecule
AVTX-803 is one of 85 small molecule programs targeting Safety and Efficacy. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
84
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
228 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Savaysa
Daiichi SankyoPhase 3
Lutathera
NovartisPhase 3
HLX10
Shanghai Henlius BiotechPhase 3
NTQ5082
NNanjing Chia-tai Tianqing Pharmaceutical
Phase 3
Tpoxx
SSIGA Technologies
Phase 3
HSK39297
Haisco Pharmaceutical Group Co., Ltd.Phase 3
KN057
SSuzhou Alphamab Co., Ltd.
Phase 3
AVTX-803
AAUG Therapeutics
Phase 3
IN-B00009
HHK inno.N Corporation
Phase 3
KSI-101
KKodiak Sciences Inc
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AVTX-803. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- AAUG Therapeutics